50% upside: The small-cap ASX share that has everything going for it

Novaport Capital reckons this healthcare stock has all the tailwinds in place to make a killing.

The team at NovaPort Capital knows what they want out of the ASX shares they buy.

According to NovaPort senior analyst Tim Binsted, his team looks for 50% upside in share price over the coming three years.

And right now there is one stock that fits the bill.

"This was a stock that was trading at a discount to its earnings and valuation where we could see earnings growth over the forward period," he said in a NovaPort video.

"And we could see, relative to market, the possibility for multiple expansion, which brings the other leg to your investment upside — and that should get you 50% over the three years."

A baby lying on a pile of one hundred dollar notes

Image source: Getty Images

Industry now structured to benefit the main ASX-listed player

The stock that Binsted is bullish on is fertility assistance provider Monash IVF Group Ltd (ASX: MVF).

Believe it or not, the business was a COVID beneficiary.

"We saw a boom in babies over that period with about a 30% growth in IVF cycles from 2021 over 2020," said Binsted.

"And while levels have moderated a bit from the peak, they're still strong and Monash's forward patient pipeline is very good."

A big tailwind for Monash is that the industry structure has changed in recent years.

Two private equity investors swooped on some of Monash's biggest rivals. One bought out ASX-listed rival Virtus and the other grabbed low-cost competitor Adora from its parent company Healius Ltd (ASX: HLS).

According to Binsted, Monash can flourish now that there's "a stable industry structure". 

"The high pressure from low cost, which was pushing in and really damaging some margins around the edges from the low-cost full-service providers has now waned," he said.

"It's a much more stable market, better for pricing, and it's an environment where Monash has a chance to win market share."

Monash has about 20% market share, but this can increase with doctors who don't want to work under private equity that switch over.

Government support and overseas expansion

Out-of-pocket costs for IVF clients can be notoriously expensive, but Binsted notes that multiple governments are offering to subsidise some of the bills.

"You've got $2,000 of new funding from the good state of NSW, and we've also got the Vic liberals with that on their policy platform," he said.

"We've seen some additional funding for genetic testing coming through from the federal government for Medicare, which should flow into the pool of profits from the end of this year."

On the side, Monash also has overseas expansion that could be a source of future growth.

"We've got a growing Asia business, which is a secondary part of the story for Monash with a couple of clinics… the main one in Kuala Lumpur, which has got a couple of million dollars of earnings recovery that should come from COVID interruptions not repeating in the forward period."

The ultrasound arm is also seeing a tidy post-pandemic recovery.

"If you add that with the positive industry dynamics, the strong competitive background for Monash and the chance to win doctors, it's a really positive story for the small cap IVF sector for the next year and years afterwards."

The Monash share price is down more than 12% over the past year but is up 14.2% so far in 2023. The stock pays out a dividend yield of 4.15%.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »